ArticlePharmaceuticals (Basel, Switzerland)2023
Characterization of Non-Specific Uptake and Retention Mechanisms of [
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Salivary glands as the primary dose-limiting organ: an integrated dosimetry, efficacy, and toxicity study ofFrontiers in pharmacology · 2026Article
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.Nature reviews. Urology · 2025Review
- Molecular imaging supports the development of multispecific cancer antibodies.Nature reviews. Clinical oncology · 2024Review
- Searching for Protein Off-Targets of Prostate-Specific Membrane Antigen-Targeting Radioligands in the Salivary Glands.Cancer biotherapy & radiopharmaceuticals · 2024Article
- Single Chelator-Minibody Theranostic Agents forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target.Chemical science · 2024Article
- Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?Pharmaceuticals (Basel, Switzerland) · 2024Article
- Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m.International journal of molecular sciences · 2024Article
- Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies.BJUI compass · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The radionuclide therapy [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.